rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

ARCH Venture Fund X, L.P.

10% owner

Company insider

Files Form 4 as: 10% owner, Aspen Neuroscience; 10% owner, Sana Biotechnology.

Every Form 4 they filed

In numbers

Trades disclosed
38
Buys
2
Sells
0
Bought
$30.0M
Sold
$0
Companies
2
Companies where not an officer
2
First trade
8 Feb 2021
Last trade
2 Nov 2026
Last filed
2 Nov 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ASPE Aspen Neuroscience10% owner · Biotechnology · last 2 Nov 20261 buy · 0 sells
SANA Sana Biotechnology10% owner · Biotechnology · last 8 Feb 20241 buy · 0 sells

Activity over time

1 Dec 2024 – 1 Nov 2026
01Dec 24Jun 25Dec 25May 26Nov 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Bought$1000K66,666 at $15.00filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—295,490filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—214,355filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Bought$18.0M1,200,000 at $15.00filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—187,182filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—298,258filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—298,258filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—286,304filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—286,304filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—295,490filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—295,490filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—187,182filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—259,948filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code C—214,355filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—298,258filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—286,304filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—295,490filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—259,948filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Bought$1.0M66,667 at $15.00filing
2 Nov 2026filed 2 Nov 2026ASPE Aspen NeuroscienceBiotechnologySEC FORM 4 Code C—298,258filing

News

Aspen Neuroscience (ASPE) raises $140.6 million in Nasdaq IPO at $15ASPE · 247wallst.com · 30 Oct 2026

0 headlines in the last 90 days name ARCH Venture Fund X, L.P.; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Faheem HasnainExecutive Chair · Executive Chair at Aspen Neuroscience, filing Form 4 there in the last year
Andrew SpaventaDirector · Director at Aspen Neuroscience, filing Form 4 there in the last year
ARCH Venture Partners XIV, L.P.10% owner · 10% owner at Aspen Neuroscience, filing Form 4 there in the last year